Skip to main content
Top
Published in: Archives of Osteoporosis 1/2019

01-12-2019 | Bisphosphonate | Original Article

Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis—a retrospective-prospective study from southern India

Authors: Basavaraj Sooragonda, Kripa Elizabeth Cherian, Felix K. Jebasingh, Riddhi Dasgupta, Hesarghatta S. Asha, Nitin Kapoor, Nihal Thomas, Thomas V. Paul

Published in: Archives of Osteoporosis | Issue 1/2019

Login to get access

Abstract

Summary

This study from southern India showed that yearly administration of zoledronic acid demonstrated significant improvement in BMD at lumbar spine following two doses and no decline in BMD at femoral neck or hip and trabecular bone score (TBS) in postmenopausal women.

Purpose

There is limited information available with regard to the impact of zoledronic acid treatment on bone mineral density (BMD) and trabecular bone score (TBS) in Indian postmenopausal women with osteoporosis. We studied the changes in BMD at femoral neck (FN), hip and lumbar spine (LS), and in TBS following yearly administration of zoledronic acid (ZA) in subjects with postmenopausal osteoporosis.

Material and methods

This was a prospective-retrospective study which included subjects on follow-up after administration of yearly zoledronic acid, over the past 6 years. Postmenopausal women with a T score of ≤ − 2.5 at any site, assessed by dual energy X-ray absorptiometry (DXA), were included.

Results

A total of 620 subjects had received ZA during the study period, 197 postmenopausal women were eligible, and follow-up data were available in 164 and 103 at 1st and 2nd follow-up yearly visits respectively. The mean (SD) age and BMI of the women were 63.2 (8.5) years and 25.6 (4.5) kg/m2 respectively. There was significant increment in LS BMD from baseline to the 1st and 2nd follow-up visits, respectively (mean (SD), 0.718 (0.116), 0.734 (0.104), 0.762 (0.127) g/cm2, p = 0.024). No decline in the BMD at FN and hip at first and second follow visit was found. The TBS scores (n = 90) on baseline and follow-up visits were 1.260 (±0.11), 1.256 (± 0.15), and 1.242 (± 0.17) (p value = 0.71).

Conclusion

Lumbar spine BMD showed significant improvement with zoledronic acid treatment. No decline was noted in femoral neck BMD and TBS with treatment.
Literature
1.
go back to reference Dhanwal DK, Siwach R, Dixit V, Mithal A, Jameson K, Cooper C (2013) Incidence of hip fracture in Rohtak district, North India. Arch Osteoporos 8:135CrossRef Dhanwal DK, Siwach R, Dixit V, Mithal A, Jameson K, Cooper C (2013) Incidence of hip fracture in Rohtak district, North India. Arch Osteoporos 8:135CrossRef
2.
go back to reference Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRef Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRef
3.
go back to reference Higgs R (2010) Osteoporosis: zoledronic acid for osteoporosis treatment--a matter of time. Nat Rev Rheumatol 6(7):382CrossRef Higgs R (2010) Osteoporosis: zoledronic acid for osteoporosis treatment--a matter of time. Nat Rev Rheumatol 6(7):382CrossRef
4.
go back to reference Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282CrossRef Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282CrossRef
5.
go back to reference Handa R (2004) Management of osteoporosis: the Indian perspective. Clin Calcium 14(9):100–105PubMed Handa R (2004) Management of osteoporosis: the Indian perspective. Clin Calcium 14(9):100–105PubMed
6.
go back to reference Mithal A, Kaur P (2012) Osteoporosis in Asia: a call to action. Curr Osteoporos Rep 10(4):245–247CrossRef Mithal A, Kaur P (2012) Osteoporosis in Asia: a call to action. Curr Osteoporos Rep 10(4):245–247CrossRef
7.
go back to reference Shetty S, Kapoor N, Naik D, Asha HS, Thomas N, Paul TV (2014) The impact of the Hologic vs the ICMR database in diagnosis of osteoporosis among south Indian subjects. Clin Endocrinol 81(4):519–522CrossRef Shetty S, Kapoor N, Naik D, Asha HS, Thomas N, Paul TV (2014) The impact of the Hologic vs the ICMR database in diagnosis of osteoporosis among south Indian subjects. Clin Endocrinol 81(4):519–522CrossRef
8.
go back to reference Cherian KE, Kapoor N, Asha HS, Thomas N, Paul TV (2018) Influence of different reference databases on categorization of bone mineral density: a study on rural postmenopausal women from southern India. Indian J Endocrinol Metab 22(5):579–583CrossRef Cherian KE, Kapoor N, Asha HS, Thomas N, Paul TV (2018) Influence of different reference databases on categorization of bone mineral density: a study on rural postmenopausal women from southern India. Indian J Endocrinol Metab 22(5):579–583CrossRef
9.
go back to reference Mithal A, Bansal B, Kyer CS, Ebeling P (2014) The Asia-Pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: a report of International Osteoporosis Foundation. Indian J Endocrinol Metab 18(4):449–454CrossRef Mithal A, Bansal B, Kyer CS, Ebeling P (2014) The Asia-Pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: a report of International Osteoporosis Foundation. Indian J Endocrinol Metab 18(4):449–454CrossRef
10.
go back to reference Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg M-A (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom Off J Int Soc Clin Densitom 14(3):302–312CrossRef Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg M-A (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom Off J Int Soc Clin Densitom 14(3):302–312CrossRef
11.
go back to reference Shin M-S, Cho E-H, Kim HY (2017) Longitudinal change in trabecular bone score during and after treatment of osteoporosis in postmenopausal Korean women. J Bone Metab 24(2):117–124CrossRef Shin M-S, Cho E-H, Kim HY (2017) Longitudinal change in trabecular bone score during and after treatment of osteoporosis in postmenopausal Korean women. J Bone Metab 24(2):117–124CrossRef
12.
go back to reference Dufour R, Winzenrieth R, Heraud A, Hans D, Mehsen N (2013) Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 24(11):2837–2846CrossRef Dufour R, Winzenrieth R, Heraud A, Hans D, Mehsen N (2013) Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 24(11):2837–2846CrossRef
13.
go back to reference Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res Off J Am Soc Bone Miner Res 29(3):518–530CrossRef Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res Off J Am Soc Bone Miner Res 29(3):518–530CrossRef
14.
go back to reference Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res Off J Am Soc Bone Miner Res 27(2):243–254CrossRef Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res Off J Am Soc Bone Miner Res 27(2):243–254CrossRef
15.
go back to reference Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res Off J Am Soc Bone Miner Res 30(5):934–944CrossRef Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res Off J Am Soc Bone Miner Res 30(5):934–944CrossRef
16.
go back to reference Huang S, Lin H, Zhu X, Chen X, Fan L, Liu C (2014) Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Endokrynol Pol 65(2):96–104CrossRef Huang S, Lin H, Zhu X, Chen X, Fan L, Liu C (2014) Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Endokrynol Pol 65(2):96–104CrossRef
17.
go back to reference Lips P, van Schoor NM (2011) The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 25(4):585–591CrossRef Lips P, van Schoor NM (2011) The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 25(4):585–591CrossRef
18.
go back to reference Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85(5):398–404CrossRef Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85(5):398–404CrossRef
19.
go back to reference Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE et al (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 20(2):239–244CrossRef Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE et al (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 20(2):239–244CrossRef
20.
go back to reference Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Nakamura Y, Kato H (2015) Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res 27(4):413–418CrossRef Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Nakamura Y, Kato H (2015) Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res 27(4):413–418CrossRef
Metadata
Title
Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis—a retrospective-prospective study from southern India
Authors
Basavaraj Sooragonda
Kripa Elizabeth Cherian
Felix K. Jebasingh
Riddhi Dasgupta
Hesarghatta S. Asha
Nitin Kapoor
Nihal Thomas
Thomas V. Paul
Publication date
01-12-2019
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2019
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-019-0630-1

Other articles of this Issue 1/2019

Archives of Osteoporosis 1/2019 Go to the issue